MY195343A - A Novel Phtalazinone Derivatives and Manufacturing Process Thereof - Google Patents
A Novel Phtalazinone Derivatives and Manufacturing Process ThereofInfo
- Publication number
- MY195343A MY195343A MYPI2016700730A MYPI2016700730A MY195343A MY 195343 A MY195343 A MY 195343A MY PI2016700730 A MYPI2016700730 A MY PI2016700730A MY PI2016700730 A MYPI2016700730 A MY PI2016700730A MY 195343 A MY195343 A MY 195343A
- Authority
- MY
- Malaysia
- Prior art keywords
- novel
- manufacturing process
- derivatives
- phtalazinone
- phtalazinone derivatives
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title 1
- IJAPPYDYQCXOEF-UHFFFAOYSA-N phthalazin-1(2H)-one Chemical class C1=CC=C2C(=O)NN=CC2=C1 IJAPPYDYQCXOEF-UHFFFAOYSA-N 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20130110170 | 2013-09-13 | ||
| KR1020140120152A KR101670126B1 (ko) | 2013-09-13 | 2014-09-11 | 신규 프탈라지논 유도체 및 그 제조방법 |
| PCT/KR2014/008523 WO2015037939A1 (en) | 2013-09-13 | 2014-09-12 | A novel phtalazinone derivatives and manufacturing process thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY195343A true MY195343A (en) | 2023-01-13 |
Family
ID=53024930
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2016700730A MY195343A (en) | 2013-09-13 | 2014-09-12 | A Novel Phtalazinone Derivatives and Manufacturing Process Thereof |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | USRE49338E1 (OSRAM) |
| EP (1) | EP3030557B1 (OSRAM) |
| JP (1) | JP6180643B2 (OSRAM) |
| KR (1) | KR101670126B1 (OSRAM) |
| CN (1) | CN105793248B (OSRAM) |
| AU (1) | AU2014319132C1 (OSRAM) |
| BR (1) | BR112016004979B1 (OSRAM) |
| CA (1) | CA2923614C (OSRAM) |
| DK (1) | DK3030557T3 (OSRAM) |
| ES (1) | ES2953834T3 (OSRAM) |
| FI (1) | FI3030557T3 (OSRAM) |
| HR (1) | HRP20230998T1 (OSRAM) |
| HU (1) | HUE062770T2 (OSRAM) |
| IL (1) | IL244548B (OSRAM) |
| LT (1) | LT3030557T (OSRAM) |
| MX (1) | MX379467B (OSRAM) |
| MY (1) | MY195343A (OSRAM) |
| PL (1) | PL3030557T3 (OSRAM) |
| PT (1) | PT3030557T (OSRAM) |
| RS (1) | RS64477B1 (OSRAM) |
| RU (1) | RU2636585C2 (OSRAM) |
| SG (1) | SG11201600549TA (OSRAM) |
| SI (1) | SI3030557T1 (OSRAM) |
| SM (1) | SMT202300268T1 (OSRAM) |
| WO (1) | WO2015037939A1 (OSRAM) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101670126B1 (ko) * | 2013-09-13 | 2016-10-27 | 일동제약(주) | 신규 프탈라지논 유도체 및 그 제조방법 |
| JP2021516229A (ja) | 2018-02-28 | 2021-07-01 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 低親和性ポリ（ａｄ−リボース）ポリメラーゼ１依存性細胞毒性剤 |
| CN115702151B (zh) * | 2020-04-21 | 2025-03-11 | 伊迪恩斯股份有限公司 | 酞嗪酮化合物的结晶形式 |
| EP4139298A4 (en) * | 2020-04-21 | 2024-05-22 | Idience Co., Ltd. | Process for preparing a phthalazinone derivative and intermediates thereof |
| WO2021225407A1 (ko) * | 2020-05-08 | 2021-11-11 | 주식회사 티씨노바이오사이언스 | 엑토뉴클레오티드 피로포스파타아제-포스포디에스터라아제의 저해 활성을 갖는 신규한 프탈라진 유도체 및 이들의 용도 |
| US12059419B2 (en) * | 2020-10-16 | 2024-08-13 | Idience Co., Ltd. | Pharmaceutical composition comprising phthalazinone derivatives |
| US20230391752A1 (en) * | 2020-10-22 | 2023-12-07 | Chulalongkorn University | Pyrrolidine-3-carboxamide derivatives and related uses |
| KR20220125183A (ko) | 2021-03-04 | 2022-09-14 | 아이디언스 주식회사 | Parp 억제제에 내성을 가진 환자군의 암 치료제로서의 프탈라지논 유도체의 항암제 용도 |
| TWI883310B (zh) * | 2021-03-04 | 2025-05-11 | 南韓商愛迪恩斯股份有限公司 | 酞嗪酮化合物在製備用於治療人類奧拉帕尼抗藥性癌症之藥物的用途 |
| US20250312342A1 (en) * | 2021-06-02 | 2025-10-09 | Idience Co., Ltd. | Methods of treating disorders with phthalazinone derivatives |
| US20250120970A1 (en) * | 2022-01-25 | 2025-04-17 | Idience Co., Ltd. | Pharmaceutical composition including phthalazinone derivative for co-administration with anticancer drug |
| WO2024025389A1 (ko) * | 2022-07-29 | 2024-02-01 | 아이디언스 주식회사 | 프탈라지논 유도체의 중간체의 제조방법 |
| CN117229260B (zh) * | 2023-11-13 | 2024-02-27 | 中国药科大学 | DNA聚合酶θ与聚ADP核糖聚合酶1双靶点抑制剂及其制备方法和医药用途 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL155645A0 (en) | 2000-10-30 | 2003-11-23 | Kudos Pharm Ltd | Phthalazinone derivatives |
| JP4500161B2 (ja) | 2002-04-30 | 2010-07-14 | クドス ファーマシューティカルズ リミテッド | フタラジノン誘導体 |
| US7449464B2 (en) | 2003-03-12 | 2008-11-11 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| EP1633724B1 (en) * | 2003-03-12 | 2011-05-04 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| GB0610680D0 (en) | 2006-05-31 | 2006-07-12 | Istituto Di Ricerche D Biolog | Therapeutic compounds |
| AU2007266840B2 (en) | 2006-05-31 | 2012-09-20 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Pyrrolo[1,2-A]pyrazin-1(2H)-one and pyrrolo[1,2-D][1,2,4]triazin-1(2H)-one derivatives as inhibitors of poly(ADP-ribose)polymerase(PARP) |
| DK2698062T3 (en) | 2006-12-28 | 2015-09-14 | Abbvie Inc | Poly (ADP-ribose) polymerase inhibitors |
| CN101030723A (zh) | 2007-04-04 | 2007-09-05 | 钟志华 | 电磁变相发动机 |
| ES2524787T3 (es) | 2007-11-15 | 2014-12-12 | Msd Italia S.R.L. | Derivados de piridazinona como inhibidores de PARP |
| AR070221A1 (es) * | 2008-01-23 | 2010-03-25 | Astrazeneca Ab | Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas. |
| GB0804755D0 (en) | 2008-03-14 | 2008-04-16 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| WO2012014221A1 (en) | 2010-07-27 | 2012-02-02 | Cadila Healthcare Limited | Substituted 4-(4-fluoro-3-(piperazine-1- carbonyl)benzyl)phthalazin-1(2h)-one derivatives as poly (adp-ribose) polymerase- 1 inhibitors |
| CN102372706A (zh) * | 2010-08-09 | 2012-03-14 | 江苏恒瑞医药股份有限公司 | 酞嗪酮类衍生物、其制备方法及其在医药上的应用 |
| CN102372716A (zh) | 2010-08-09 | 2012-03-14 | 江苏恒瑞医药股份有限公司 | 酞嗪酮类衍生物、其制备方法及其在医药上的应用 |
| CN102372698A (zh) | 2010-08-10 | 2012-03-14 | 江苏恒瑞医药股份有限公司 | 酞嗪酮类衍生物、其制备方法及其在医药上的应用 |
| US8999985B2 (en) * | 2010-12-02 | 2015-04-07 | Shanghai De Novo Pharmatech Co Ltd. | Substituted phthalazin-1(2H)-ones, preparation processes and medical uses thereof |
| CN102485721B (zh) | 2010-12-03 | 2015-12-09 | 曹亚 | 取代的2,3-二氮杂萘酮化合物及其用途 |
| CN103130723B (zh) * | 2011-11-30 | 2015-01-14 | 成都地奥制药集团有限公司 | 一种多聚(adp-核糖)聚合酶抑制剂 |
| KR101670126B1 (ko) * | 2013-09-13 | 2016-10-27 | 일동제약(주) | 신규 프탈라지논 유도체 및 그 제조방법 |
-
2014
- 2014-09-11 KR KR1020140120152A patent/KR101670126B1/ko active Active
- 2014-09-12 HU HUE14843941A patent/HUE062770T2/hu unknown
- 2014-09-12 CN CN201480049174.5A patent/CN105793248B/zh active Active
- 2014-09-12 MY MYPI2016700730A patent/MY195343A/en unknown
- 2014-09-12 FI FIEP14843941.7T patent/FI3030557T3/fi active
- 2014-09-12 SM SM20230268T patent/SMT202300268T1/it unknown
- 2014-09-12 ES ES14843941T patent/ES2953834T3/es active Active
- 2014-09-12 EP EP14843941.7A patent/EP3030557B1/en active Active
- 2014-09-12 MX MX2016002998A patent/MX379467B/es unknown
- 2014-09-12 RU RU2016108038A patent/RU2636585C2/ru active
- 2014-09-12 JP JP2016542643A patent/JP6180643B2/ja active Active
- 2014-09-12 US US16/447,174 patent/USRE49338E1/en active Active
- 2014-09-12 LT LTEPPCT/KR2014/008523T patent/LT3030557T/lt unknown
- 2014-09-12 DK DK14843941.7T patent/DK3030557T3/da active
- 2014-09-12 AU AU2014319132A patent/AU2014319132C1/en active Active
- 2014-09-12 CA CA2923614A patent/CA2923614C/en active Active
- 2014-09-12 HR HRP20230998TT patent/HRP20230998T1/hr unknown
- 2014-09-12 BR BR112016004979-9A patent/BR112016004979B1/pt active IP Right Grant
- 2014-09-12 SG SG11201600549TA patent/SG11201600549TA/en unknown
- 2014-09-12 RS RS20230721A patent/RS64477B1/sr unknown
- 2014-09-12 US US15/021,336 patent/US9682973B2/en active Active
- 2014-09-12 PT PT148439417T patent/PT3030557T/pt unknown
- 2014-09-12 WO PCT/KR2014/008523 patent/WO2015037939A1/en not_active Ceased
- 2014-09-12 SI SI201432038T patent/SI3030557T1/sl unknown
- 2014-09-12 PL PL14843941.7T patent/PL3030557T3/pl unknown
-
2016
- 2016-03-11 IL IL244548A patent/IL244548B/en active IP Right Grant
-
2017
- 2017-03-10 US US15/455,631 patent/US9844550B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY195343A (en) | A Novel Phtalazinone Derivatives and Manufacturing Process Thereof | |
| PH12017500408B1 (en) | Heteroaryl compounds as btk inhibitors and uses thereof | |
| PH12014000179A1 (en) | New pyrrole compounds, a process for their preparation and pharmaceutical compositions containing them | |
| MX2016016666A (es) | Derivados de acido boronico y usos terapeuticos de los mismos. | |
| MX2016015093A (es) | Derivados de acido boronico y sus usos terapeuticos. | |
| JO3419B1 (ar) | مركبات بيريدوبيرازين مضادة للسرطان من خلال تثبيط إنزيمات كيناز fgfr | |
| MX378194B (es) | Compuestos organicos. | |
| PH12014501967B1 (en) | Benzodioxanes in combination with other actives for inhibiting leukotriene production | |
| MX2017014035A (es) | Formas solidas novedosas. | |
| MX2021011906A (es) | Composiciones de liberacion retardada de linaclotida. | |
| MX2014014832A (es) | Pirrolopirimidona y pirrolopiridona, inhibidores de tanquirasa. | |
| WO2014121764A3 (en) | 2-substituted-6-biarylmethylamino-9-cyclopentyl-9h-purine derivatives, use thereof as medicaments, and pharmaceutical compositions | |
| UA117020C2 (uk) | Нові сполуки індолу і піролу, спосіб їх одержання і фармацевтичні композиції, що їх містять | |
| EP3034082A4 (en) | Pharmaceutical composition for treating or preventing neuropsychitric disease, containing flavone-6-c-glucose derivatives as active ingredients | |
| HK1222325A1 (zh) | 高效的胰酶藥物組合物 | |
| MX2015003034A (es) | Jeringa que contiene una composicion, en particular farmaceutica, que comprende inmunoglobulinas, su metodo de fabricacion y uso. | |
| MX2014004210A (es) | Derivados de 2-oxo-piperidinilo. | |
| MX2013013436A (es) | Derivados de indol sustituidos para el tratamiento de transtornos inmunologicos. | |
| MX2015016603A (es) | Composiciones de corticosteroides. | |
| MX371158B (es) | Compuestos inhibidores de pde2. | |
| AU2013338098A8 (en) | Solid salt form of alpha-6-mPEG6-O-hydroxycodone as opioid agonists and uses thereof | |
| WO2014159501A3 (en) | Processes for preparing tetrahydroisoquinolines | |
| WO2014122671A3 (en) | Solid oral compositions of saxagliptin | |
| HK1250020A1 (zh) | 用於吡咯连接的二价化合物的化学合成的方法及其组合物 | |
| IN2015DN02660A (OSRAM) |